CN104144921A - 药物化合物 - Google Patents
药物化合物 Download PDFInfo
- Publication number
- CN104144921A CN104144921A CN201280066542.8A CN201280066542A CN104144921A CN 104144921 A CN104144921 A CN 104144921A CN 201280066542 A CN201280066542 A CN 201280066542A CN 104144921 A CN104144921 A CN 104144921A
- Authority
- CN
- China
- Prior art keywords
- compound
- acid
- benzo
- methyl
- isopentyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1119538.5 | 2011-11-10 | ||
GBGB1119538.5A GB201119538D0 (en) | 2011-11-10 | 2011-11-10 | Pharmaceutical compounds |
PCT/GB2012/052806 WO2013068769A1 (en) | 2011-11-10 | 2012-11-12 | Pharmaceutical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104144921A true CN104144921A (zh) | 2014-11-12 |
CN104144921B CN104144921B (zh) | 2016-08-24 |
Family
ID=45421672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280066542.8A Active CN104144921B (zh) | 2011-11-10 | 2012-11-12 | 药物化合物 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9809575B2 (zh) |
EP (1) | EP2776416B1 (zh) |
JP (1) | JP6046735B2 (zh) |
KR (1) | KR101996335B1 (zh) |
CN (1) | CN104144921B (zh) |
CA (1) | CA2855204C (zh) |
CY (1) | CY1117428T1 (zh) |
DK (1) | DK2776416T3 (zh) |
ES (1) | ES2568476T3 (zh) |
GB (1) | GB201119538D0 (zh) |
HR (1) | HRP20160374T1 (zh) |
HU (1) | HUE028747T2 (zh) |
IN (1) | IN2014DN04647A (zh) |
PL (1) | PL2776416T3 (zh) |
RU (1) | RU2612530C2 (zh) |
SI (1) | SI2776416T1 (zh) |
WO (1) | WO2013068769A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104903313B (zh) * | 2012-10-16 | 2017-12-29 | 爱尔兰詹森科学公司 | Rsv抗病毒化合物 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2910508A1 (en) * | 2013-05-14 | 2014-11-20 | Song Feng | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
EP3033341B1 (en) | 2013-08-12 | 2017-05-03 | F. Hoffmann-La Roche AG | Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
CN105408330A (zh) * | 2013-08-12 | 2016-03-16 | 豪夫迈·罗氏有限公司 | 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚 |
MX2016001858A (es) * | 2013-08-15 | 2016-05-24 | Hoffmann La Roche | Aza-oxo-indoles novedosos para el tratamiento y profilaxis de la infeccion por el virus sincicial respiratorio. |
EP3081569B1 (en) | 2013-12-10 | 2019-09-18 | Shandong Danhong Pharmaceutical Co., Ltd. | Imidazole derivative used as antiviral agent and use thereof in preparation of medicament |
TWI671299B (zh) * | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為rsv抗病毒化合物之螺脲化合物 |
GB201417707D0 (en) * | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
JP6548751B2 (ja) | 2015-06-08 | 2019-07-24 | シャンドン ダンホン ファーマスーティカル カンパニー リミテッドShandong Danhong Pharmaceutical Co., Ltd. | イミダゾール誘導体及びその中間体の製造及び結晶型 |
EP4360707A2 (en) | 2015-11-12 | 2024-05-01 | F. Hoffmann-La Roche AG | Compositions for treating spinal muscular atrophy |
WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
EP3848035A1 (en) | 2015-12-10 | 2021-07-14 | PTC Therapeutics, Inc. | 1,4-disubstituted pyridazine compounds for treating huntington's disease |
RS61963B1 (sr) | 2016-08-04 | 2021-07-30 | Reviral Ltd | Derivati pirimidina i njihova upotreba u lečenju ili prevenciji infekcije respiratornog sincicijalnog virusa |
SG11201911615WA (en) | 2017-06-05 | 2020-01-30 | Ptc Therapeutics Inc | Compounds for treating huntington's disease |
CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
GB201711704D0 (en) * | 2017-07-20 | 2017-09-06 | Reviral Ltd | Pharmaceutical compounds |
GB201721812D0 (en) | 2017-12-22 | 2018-02-07 | Reviral Ltd | Pharmaceutical compounds |
WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
JP7421507B2 (ja) | 2018-06-27 | 2024-01-24 | ピーティーシー セラピューティクス, インコーポレイテッド | ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物 |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
US20020099208A1 (en) * | 2000-12-20 | 2002-07-25 | Kuo-Long Yu | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
CN1898247A (zh) * | 2003-12-24 | 2007-01-17 | 生物区科学管理控股有限公司 | 用于治疗呼吸道合胞体病毒感染的多环试剂 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2184735C2 (ru) * | 1998-01-23 | 2002-07-10 | Санкио Компани, Лимитед | Производные спиропиперидина, лекарственное средство, способ профилактики или лечения |
CZ20014574A3 (cs) | 1999-06-28 | 2002-05-15 | Janssen Pharmaceutica N. V. | Inhibitory replikace respiračně syncyciálního viru |
US6369076B1 (en) * | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
PA8535601A1 (es) * | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
US6919331B2 (en) | 2001-12-10 | 2005-07-19 | Bristol-Myers Squibb Company | Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents |
WO2010103306A1 (en) | 2009-03-10 | 2010-09-16 | Astrazeneca Uk Limited | Benzimidazole derivatives and their use as antivaral agents |
WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
-
2011
- 2011-11-10 GB GBGB1119538.5A patent/GB201119538D0/en not_active Ceased
-
2012
- 2012-11-12 US US14/357,293 patent/US9809575B2/en active Active
- 2012-11-12 IN IN4647DEN2014 patent/IN2014DN04647A/en unknown
- 2012-11-12 JP JP2014540557A patent/JP6046735B2/ja active Active
- 2012-11-12 EP EP12787847.8A patent/EP2776416B1/en active Active
- 2012-11-12 PL PL12787847T patent/PL2776416T3/pl unknown
- 2012-11-12 WO PCT/GB2012/052806 patent/WO2013068769A1/en active Application Filing
- 2012-11-12 RU RU2014123434A patent/RU2612530C2/ru active
- 2012-11-12 CA CA2855204A patent/CA2855204C/en active Active
- 2012-11-12 KR KR1020147015742A patent/KR101996335B1/ko active IP Right Grant
- 2012-11-12 CN CN201280066542.8A patent/CN104144921B/zh active Active
- 2012-11-12 ES ES12787847.8T patent/ES2568476T3/es active Active
- 2012-11-12 HU HUE12787847A patent/HUE028747T2/en unknown
- 2012-11-12 DK DK12787847.8T patent/DK2776416T3/en active
- 2012-11-12 SI SI201230521A patent/SI2776416T1/sl unknown
-
2016
- 2016-04-12 CY CY20161100308T patent/CY1117428T1/el unknown
- 2016-04-12 HR HRP20160374TT patent/HRP20160374T1/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4044136A (en) * | 1972-09-09 | 1977-08-23 | Pfizer Inc. | Aminoquinazoline therapeutic agents |
US20020099208A1 (en) * | 2000-12-20 | 2002-07-25 | Kuo-Long Yu | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
CN1898247A (zh) * | 2003-12-24 | 2007-01-17 | 生物区科学管理控股有限公司 | 用于治疗呼吸道合胞体病毒感染的多环试剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104903313B (zh) * | 2012-10-16 | 2017-12-29 | 爱尔兰詹森科学公司 | Rsv抗病毒化合物 |
Also Published As
Publication number | Publication date |
---|---|
GB201119538D0 (en) | 2011-12-21 |
IN2014DN04647A (zh) | 2015-05-15 |
SI2776416T1 (sl) | 2016-06-30 |
US20140308282A1 (en) | 2014-10-16 |
KR101996335B1 (ko) | 2019-07-04 |
HRP20160374T1 (hr) | 2016-06-03 |
JP2014533257A (ja) | 2014-12-11 |
ES2568476T3 (es) | 2016-04-29 |
US9809575B2 (en) | 2017-11-07 |
CA2855204C (en) | 2020-06-16 |
HUE028747T2 (en) | 2016-12-28 |
EP2776416A1 (en) | 2014-09-17 |
EP2776416B1 (en) | 2016-01-13 |
DK2776416T3 (en) | 2016-04-18 |
CA2855204A1 (en) | 2013-05-16 |
CN104144921B (zh) | 2016-08-24 |
WO2013068769A1 (en) | 2013-05-16 |
PL2776416T3 (pl) | 2017-01-31 |
RU2014123434A (ru) | 2015-12-20 |
KR20140128292A (ko) | 2014-11-05 |
CY1117428T1 (el) | 2017-04-26 |
RU2612530C2 (ru) | 2017-03-09 |
JP6046735B2 (ja) | 2016-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104144921A (zh) | 药物化合物 | |
JP6843103B2 (ja) | グルタルイミド誘導体、その使用、それに基づいた医薬組成物及びグルタルイミド誘導体を製造するための方法 | |
CN106854205B (zh) | 流感病毒复制抑制剂及其使用方法和用途 | |
CN103282366B (zh) | 用于治疗呼吸道合胞病毒感染的化合物 | |
JP2017531039A (ja) | 新規5,6−ジヒドロ−4H−ベンゾ[b]チエノ−[2,3−d]アゼピン誘導体 | |
BR112021014079A2 (pt) | Ácidos carboxílicos policíclicos substituídos, análogos dos mesmos e métodos usando os mesmos | |
TW201117812A (en) | Macrocyclic serine protease inhibitors | |
JP2019519616A (ja) | 化合物 | |
ES2937837T3 (es) | Inhibidores de piridopirazina y piridotriazina de la replicación del virus de la gripe | |
JP5340943B2 (ja) | 呼吸器合胞体ウイルス感染症の処置のための多環式薬剤 | |
CN106279150B (zh) | 吡啶稠环类化合物及其制备方法和用途 | |
CN105392787B (zh) | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 | |
CN114787155A (zh) | 药物化合物 | |
CN103781789B (zh) | 用于治疗呼吸道合胞病毒感染的化合物 | |
CA3106556A1 (en) | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication | |
WO2019210880A1 (zh) | 双并环脲类核衣壳抑制剂及其药物用途 | |
KR20220166745A (ko) | 펜드린 억제 활성을 갖는 신규 화합물 및 이의 의약 용도 | |
CN117794577A (zh) | 对潘特林具有抑制活性的新型化合物及其制药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: London, England Applicant after: RE:VIRAL LTD. Address before: cardiff uk Applicant before: RE:VIRAL LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Steve Niki Patentee after: REELWELL A/S Address before: London Patentee before: RE:VIRAL LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221209 Address after: New York, United States Patentee after: PFIZER Inc. Address before: Steve Niki Patentee before: REELWELL A/S |